However, flow cytometry demonstrated decreased PD-1 expression on T-cell populations after TRT/ICI, which may indicate less exhausted T cells and corresponds to recent findings in blood samples of patients with progressive metastatic castration-resistant prostate cancer who responded well to combined [177Lu]Lu-PSMA-617 and pembrolizumab treatment 34. The gene discussed is FOLH1; the disease is prostate carcinoma.